Membrane proteins control many of the interactions that allow cells to sense their environment, receive biological signals, transport molecules, and communicate with neighbouring cells. Their position on the cell surface also makes them accessible to therapeutic antibodies, immune cells, and targeted drug-delivery systems.
However, developing antibodies against these proteins is often more difficult than working with soluble targets. Effective membrane protein antibody discovery must account for protein structure, native cellular context, target density, and unintended binding to other cell-surface molecules.
As antibody therapies become more complex, researchers need screening strategies that evaluate not only whether a candidate binds, but also what it binds, where it binds, and whether the interaction remains selective in living cells.
Why Membrane Proteins Are Important Drug Targets
Membrane proteins sit at the boundary between the cell and its surrounding environment. This location allows them to transmit signals, transport nutrients, regulate ion movement, and control how cells respond to hormones, growth factors, and immune signals.
Major membrane protein categories include:
- G protein-coupled receptors
- Receptor tyrosine kinases
- Ion channels
- Transporters
- Adhesion molecules
- Immune checkpoints
- Cell-surface enzymes
- Tumour-associated antigens
For antibody developers, surface accessibility is a major advantage. An antibody does not always need to enter the cell to alter a disease-related pathway. It may block receptor activation, prevent ligand binding, recruit immune cells, or deliver a therapeutic payload to a target-expressing cell.
Monoclonal antibodies can act directly, change immune activity, or carry drugs and other therapeutic agents to selected cells.
The Native Conformation Challenge
A membrane protein does not function as an isolated amino acid sequence. Its three-dimensional shape depends partly on the lipid bilayer, surrounding proteins, post-translational modifications, and local cellular conditions.
Removing the protein from the membrane can disturb this environment. Detergent solubilisation, purification, immobilisation, or truncation may change the extracellular regions that an antibody is expected to recognise.
This issue is particularly important for multipass membrane proteins. These proteins cross the membrane several times and may form complex extracellular loops or conformational epitopes. A purified fragment may not reproduce the same structure presented on a living cell.
Research using whole-cell antibody selection has shown that cell-based methods can preserve complex membrane targets in a more biologically relevant conformation. Such methods have supported antibody discovery against difficult multipass targets, including G protein-coupled receptors.
Why Traditional Antigen Formats May Miss Useful Antibodies
Purified recombinant proteins remain valuable in antibody research, but they may favour candidates that recognise the experimental antigen rather than the native cell-surface target.
Several problems may occur:
- A purified domain may fold differently from the full-length protein.
- An immobilised antigen may hide or distort an important epitope.
- Truncated proteins may lack supporting extracellular regions.
- Detergents may affect multipass protein stability.
- Recombinant proteins may have different glycosylation patterns.
- Soluble antigens may not represent target density on cells.
An antibody may therefore perform well in an enzyme-linked immunosorbent assay yet show weak binding to the same protein on living cells. The reverse can also happen when a valuable conformational epitope is present only in the native membrane environment.
Cell-based selection combined with sequencing has successfully identified antibodies against integral membrane proteins displayed on native cells, including cancer-associated targets such as CD151 and carbonic anhydrase 9.
Live-Cell Screening Adds Biological Context
Live-cell screening allows researchers to evaluate antibody interactions while target proteins remain embedded in a cellular membrane. This preserves more of the structural and biological context that may influence binding.
A cell-based workflow can compare antibody activity across:
- Cells expressing the intended target
- Parental cells without target expression
- Cells expressing related protein-family members
- Cells with low or high target density
- Healthy and disease-relevant cell types
- Engineered cells carrying specific target variants
Positive selection identifies candidates that bind to target-expressing cells. Counter-screening removes antibodies that also bind to control cells or unrelated surface molecules.
Researchers have developed high-throughput imaging approaches that use intact target-expressing cells to preserve native membrane protein presentation. These systems can help identify antibodies with relevant cellular binding rather than relying only on purified-antigen recognition.
Specificity Matters as Much as Affinity
Affinity describes how strongly an antibody interacts with a target. Specificity describes whether it binds the intended target rather than other molecules.
A high-affinity antibody is not necessarily a safe or useful therapeutic candidate. Strong binding becomes a disadvantage when the antibody recognises a similar protein on healthy cells or interacts with an unrelated membrane target.
This concern becomes more significant when a therapy has a powerful biological mechanism. An unintended interaction may be amplified when the candidate is used as:
- An antibody-drug conjugate
- A bispecific T-cell engager
- A CAR-T recognition domain
- An immune checkpoint therapy
- An agonist antibody
- A cytotoxic or immune-activating biologic
Early specificity screening helps research teams identify problematic candidates before investing in extensive optimisation, animal studies, manufacturing development, or regulatory preparation.
It also supports more informed lead selection. Rather than choosing the antibody with the strongest target binding alone, developers can prioritise candidates that combine suitable affinity with a cleaner interaction profile.
Membrane Protein Arrays Expand Off-Target Screening
Testing an antibody against individual proteins one at a time is slow and may overlook unexpected interactions. Membrane protein arrays provide a broader method for evaluating candidate specificity.
These systems typically use collections of engineered cells, with each cell line expressing a defined membrane protein. The antibody is screened across the panel, and binding signals are compared to identify intended and unintended interactions.
One example is Kyinno’s MPSA-AB5000 platform, which uses a high-throughput cell-based format and luciferase reporter detection. The company states that its array covers more than 5,000 unique human membrane proteins, including receptors, transporters, and enzymes expressed in living cells.
A broad screening panel can help answer several development questions:
- Does the antibody bind only its intended target?
- Does it recognise closely related protein-family members?
- Are unexpected membrane proteins producing strong signals?
- Is further counter-screening required?
- Should the candidate advance, be redesigned, or be discontinued?
The results do not replace toxicology or functional safety studies. They provide an earlier layer of evidence that can guide subsequent experiments.
Cell-Based Affinity Testing Improves Candidate Evaluation
Researchers must also determine whether an antibody maintains suitable affinity when its target is presented on a cell.
Common biophysical tools such as surface plasmon resonance are highly useful for measuring interactions with purified proteins. However, results generated with soluble antigens may differ from binding behaviour on a cell surface.
Cell-based affinity methods can evaluate unmodified antibodies against receptors in their membrane-associated form. A 2025 study demonstrated an electrochemiluminescence-based method for measuring antibody affinity to cell-surface receptors while avoiding the need to purify and solubilise the target protein.
Combining purified-protein assays with live-cell measurements can provide a more complete candidate profile. Each format answers a different question:
- Purified-protein assays support detailed kinetic analysis.
- Cell-based assays assess binding in a native-like environment.
- Functional assays determine whether binding changes cell behaviour.
- Broad arrays investigate potential cross-reactivity.
Early Screening Can Improve Development Decisions
Drug discovery teams continually make decisions about which candidates deserve additional time and investment. Weak specificity data can allow technical risks to remain hidden until later stages.
Integrating membrane protein screening earlier may help teams:
- Remove cross-reactive candidates
- Compare leads using consistent data
- Investigate unexpected biological activity
- Select safer antibody formats
- Design more relevant functional assays
- Reduce unnecessary downstream studies
- Strengthen preclinical development plans
This approach is especially valuable for small biotechnology companies that must concentrate resources on a limited number of programmes. Earlier evidence can support clearer go or no-go decisions and reduce the likelihood of advancing a candidate based on affinity alone.
For larger pharmaceutical organisations, high-throughput screening may improve consistency across discovery portfolios and provide comparable specificity data for different therapeutic formats.
Looking Ahead
Membrane proteins will remain important targets for antibody therapeutics, cell therapies, diagnostics, and precision drug-delivery technologies. The challenge is to study them without losing the structural context that makes them biologically meaningful.
Future platforms will likely combine live-cell screening with sequencing, computational analysis, structural modelling, functional assays, and automated data interpretation. These integrated workflows may reveal relationships between antibody sequence, membrane target structure, cellular binding, and downstream activity.
Better technology does not eliminate the complexity of membrane proteins. It allows researchers to evaluate that complexity earlier and more systematically.
The strongest antibody candidates will not simply bind tightly. They will recognise the correct protein in its native cellular environment, avoid unintended targets, and produce the desired biological effect. By placing these requirements at the centre of discovery, research teams can build more reliable foundations for the next generation of targeted therapies.
